Moderna advances after flu vaccine panel vote, shares extend June rebound on NASDAQ

Moderna advances on NASDAQ after a positive FDA advisory committee vote on its mRNA-1010 flu vaccine candidate, while the biotech’s shares extend a strong June rebound and traders watch the next earnings date at the end of July.

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-23, 21:13.

Moderna Inc. (US60770K1034) sees renewed interest on NASDAQ as its shares react to a positive FDA advisory committee vote on the mRNA-1010 flu vaccine candidate. According to recent market commentary, this decision has supported a marked rebound in the biotech’s stock in June.Morpher analysis on Moderna and mRNA-1010

What the flu vote changed

An overview of recent coverage shows that an FDA advisory committee backed the benefit-risk profile of Moderna’s seasonal flu vaccine mRNA-1010, a key non-COVID asset in the pipeline.Morpher analysis on Moderna and mRNA-1010 The vote relates to the company’s broader effort to diversify revenue beyond its original Covid-19 vaccine.

Following the advisory outcome, several trading platforms report that Moderna shares have staged a multi-day rebound in June, with some data providers citing a gain of more than 30 percent over the past 30 days.TrendSpider data on MRNA performance This puts the stock among the notable movers inside the S&P 500 over the past month.

Consensus and next earnings date

Analyst compilations show a mixed but constructive view on Moderna, with a blend of Strong Buy, Buy, Hold and Sell recommendations and an average rating slightly above neutral.Analyst distribution via wallstreet-online.de Some summaries also note an average target price in the mid-40 US dollar range, below the current spot level.

For calendar-oriented investors, several data providers point to July 31, 2026 as the next scheduled earnings date for Moderna, when management will update on commercial uptake and research spending.TrendSpider earnings calendar for MRNA The report should give more color on how the company plans to monetize its flu and other mRNA programs beyond Covid-19.

The product behind the stock

Moderna’s original commercial breakthrough came from its Spikevax Covid-19 mRNA vaccine, but the company now highlights a broader respiratory vaccine portfolio that includes the mRNA-1010 seasonal flu candidate and combination approaches against influenza and SARS-CoV-2.Pipeline overview referencing mRNA-1010 The business model centers on mRNA platforms that can be adapted to new pathogens and indications.

Where the stock trades today

The Moderna shares (US60770K1034) trade on 2026-06-23, 13:16 on NASDAQ at 62.30 US dollars, based on consolidated quote data.Financialdata.net Moderna quote overview

Key data on the Moderna shares

• Company: Moderna Inc.
• ISIN: US60770K1034
• WKN: A2N9D9
• Ticker: MRNA
• Trading venue: NASDAQ
• Price (as of 2026-06-23, 13:16): 62.30 USD
• Market cap: 24.5 billion USD (as of 2026-06-23)
• Sector / industry: Biotechnology / Pharmaceuticals
• Index membership: S&P 500
• Next earnings date: 2026-07-31

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. Price data and dates are based on publicly available sources and may be subject to delays or subsequent revisions.